

Chordia was nominated as a finalist of the Informa Pharma Intelligence Awards Japan 2022, in two categories of “Executive of the Year” and “Biotech Company of the Year – Private”.

April 7, 2022

KANAGAWA, Japan, April 7, 2022 – Chordia today announced that our CSO, Daisuke Morishita, has been selected as a finalist for Biotech Company of the Year private and Executive of the Year in the Informa Pharma Intelligence Awards 2022.

The final award winners will be announced at the awards ceremony on Thursday, September 1, 2022. The awards ceremony, which will bring together companies that are driving the development of the healthcare industry globally, will provide an opportunity to discover new business opportunities. Chordia will continue its efforts to research and develop first-in-class anti-cancer drugs through collaboration with universities, research institutes, and companies in the healthcare industry, with the aim of creating innovative new drugs.

<SHORTLIST>

<https://pharmaintelligence.informa.com/events/awards/japan-awards-2022/shortlist-2022>



Media Contacts

Kentaro Kume

kentaro.kume@chorditherapeutics.com



About Chordia

Chordia Therapeutics Inc is an oncology drug discovery and development company focusing on advancing innovative assets to deliver transformative therapies to cancer patients since its foundation in November 2017 at Shonan Health Innovation Park, Kanagawa, Japan. Chordia's lead asset CTX-712, a CLK inhibitor, is under Phase 1 clinical study in Japan. CTX-712 potentially targets the vulnerability of cancer, and is expected to deliver benefit to patients of various types of cancer. Chordia has also multiple early-stage pipelines for targeting tumors with particular abnormalities. For additional info., please visit <https://www.chordiatherapeutics.com>.